Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

CPIX - Cumberland Pharmaceuticals Inc.... | Finranks

Home

/

CPIX

C

Cumberland Pharmaceuticals Inc. (CPIX)

NMS – Real vaqt narxi. Valyuta: USD

7.91

-0.05 (-0.63%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

8.04

+0.13 (1.64%)

Bozordan keyin: Aug 12, 2026, 4:28 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.

Videolar

No Data

There is no data to display

Press-relizlar

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.